Study Protocol for a Multicenter, Prospective, Open-Label, Randomized Controlled Trial: Effect of Riociguat Discontinuation After Combination Therapy in Patients with Chronic Thromboembolic Pulmonary Hypertension (RED-HEART Study)
The RED-HEART study is a multicenter, prospective, open-label, randomized controlled trial designed to evaluate the effects of discontinuing riociguat after combination therapy on right ventricular cardiac output and structure in patients with chronic thromboembolic pulmonary hypertension who are ineligible for pulmonary endarterectomy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine a heart struggling to pump blood against a clogged highway. In a condition called chronic thromboembolic pulmonary hypertension, old blood clots harden into scar tissue, narrowing the arteries that carry blood from the heart to the lungs. This blockage forces the right side of the heart to work overtime, eventually causing it to enlarge and fail. For patients who cannot undergo surgery to remove these blockages, doctors have two main tools: a procedure that uses balloons to widen the narrowed vessels, and a medication that helps the blood vessels relax and flow more easily. While using both tools together often works well, a critical question remains for those who have already seen their condition improve: is it safe to stop the medication once the balloons have done their work, or must the patient take the drug forever?
This is the central puzzle the "RED-HEART" study set out to solve. Researchers from five major hospitals in China designed a new clinical trial to test whether patients with this difficult heart-lung condition could safely discontinue the medication riociguat after achieving good results with a combination of balloon treatment and the drug. The study focuses on a specific group of adults whose blood pressure in the lungs has been lowered to a safe level, specifically below 30 millimeters of mercury, following their treatment. The goal was to see if stopping the drug would cause the heart's pumping power to drop, or if the improvements gained from the balloon procedure were enough to stand on their own.
The researchers recruited patients who had already undergone the balloon procedure and had been taking a stable dose of the medication for at least three months. These volunteers were then randomly assigned to one of two paths. One group continued taking the medication exactly as they had been. The other group, the "conventional treatment" group, began a carefully managed process to stop the drug. If a patient was taking a higher dose, it was slowly reduced over a month before being stopped completely; those already on a lower dose stopped immediately. Both groups then received standard supportive care, such as blood thinners and oxygen if needed, and were watched closely for six months.
The most important measure in this study was the heart's cardiac output, which is simply the total amount of blood the heart pumps out in one minute. This was measured directly using a thin tube inserted into a vein and guided into the heart, a standard and precise method for checking heart function. The researchers wanted to know if the group that stopped the medication would see a significant drop in this pumping power compared to the group that kept taking it. Alongside this primary measure, the team also tracked how far patients could walk in six minutes, their ability to perform daily tasks, and their overall quality of life. They also used non-invasive imaging, such as ultrasound and magnetic resonance scans, to look at the size and strength of the right side of the heart without needing any tubes.
This study is currently in the planning and recruitment phase, with the team expecting to finish following up with all participants by late 2027. Because the trial is still ongoing, no final results have been published yet. The researchers are working to determine if stopping the medication is a safe option for patients who have reached a specific milestone of improvement. If the study finds that the heart continues to pump strongly without the drug, it could offer a new, less burdensome path for patients, potentially saving them from the lifelong cost and side effects of daily medication. If, however, the heart function declines when the drug is stopped, it would confirm that long-term treatment is necessary to maintain the benefits of the balloon procedure.
The design of the study is rigorous, aiming to provide clear evidence rather than just suggestions. By comparing two groups of patients who are nearly identical at the start, the researchers can isolate the effect of stopping the medication. They are paying close attention to safety, monitoring for any signs of the heart failing or blood pressure dropping too low. The hope is that the findings will help doctors make more confident decisions, moving away from a "one size fits all" approach to a strategy that is tailored to each patient's specific recovery. For the patients involved, this research represents a chance to understand if they can eventually return to a life without daily medication, provided their hearts have healed enough to do so.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.